MedTrace Logo

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

NCT01041625 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2010-01-01

No results posted yet for this study

Summary

This study is designed to demonstrate to efficacy and safety of Apremilast 20mg oral administration twice daily over 12 weeks in subjects with moderate to severe lichen planus. The hypothesis is that the subjects will achieve a significant clinical improvement in their skin disease according to a specialized physician grading scale.

Conditions

  • Lichen Planus

Interventions

DRUG

Apremilast (CC-10004)

Apremilast 20 mg tablet PO administered BID over 12 weeks

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Virginia Clinical Research, Inc.

    lead OTHER

Principal Investigators

  • David M Pariser, MD · Virginia Clinical Research, Inc.

  • Clare E Foss, MD · Eastern Virginia Medical School

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01041625 on ClinicalTrials.gov